Ankur Drugs and Pharma Ltd, a leading player in Contract Manufacturing, is going ahead with a major expansion programme to cater the domestic as well as international clients. The company invested Rs 135 crore for its new manufacturing facility at Baddi (HP). The construction work of the facility is already over and the plant is likely to commission shortly.
While talking with Pharmabiz Girraj Vijayvargiya, director, said, "We will start manufacturing in Baddi within couple of months. We have imported machinery from Germany and Italy. for the injectable product". In addition to traditional products, the company will also undertaking manufacturing of injectables. "Recently we have undertaken contract manufacturing for Sandoz. We are doing contract manufacturing for leading Indian players like Ranbaxy, Cipla, Cadila, Lyka, Wockhardt, Glenmark, and Torrent," he added.
Baddi plant is being set up as per US FDA and UK.MHRA standards. "We are expecting approval from regulatory bodies which will boost our contract manufacturing activity for MNCs" added Vijayvargiya.
Currently, Ankur has capability to produce 250 pharmaceutical products. The company is producing Cephalosporin tablets, capsules, dry-syrups, liquids, and ointments at its Ankleshwar plant in Gujarat. Its Baddi plant will undertake production of sterile products for the first time to meet the demand of domestic as well as international market. Ankur is focusing more on the Anti-bacterial sectors, generics, and Cephalosporins
Ankur has issued $ 16 million Foreign Currency Convertible Bonds (FCCBs) to part finance Baddi plant.
Ankur has commenced operations of small R&D facility at Daman, which will help to reduce cost of existing formulations.